XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease. It is taken orally.
The drug is a dopamine D<sub>2</sub> receptor partial agonist, a dopamine D<sub>3</sub> receptor antagonist, an ñ<sub>1A</sub>-adrenergic receptor antagonist, and a serotonin 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2B</sub> receptor antagonist. Its potency as a dopamine D<sub>2</sub> receptor agonist is similar to that of lisuride. XC-130 produces antiparkinsonian-like effects in animals. Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessiveâÂÂcompulsive symptoms (related to D<sub>3</sub> agonism), vasoconstriction (related to ñ<sub>1A</sub>-adrenergic and 5-HT<sub>1B</sub> agonism), hallucinogenic effects (related to 5-HT<sub>2A</sub> agonism), and cardiac valvulopathy (related to 5-HT<sub>2B</sub> agonism). It has a notably longer elimination half-life than the relatively short-acting lisuride. The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile.
XC-130 is under development by Xoc Pharmaceuticals. As of November 2022, it is in phase 1/2 clinical trials. The chemical structure of XC-130 does not yet appear to have been disclosed.